The aim of ICI treatment is to lift the restriction of tumor cells on CTL, and the prediction of response indicated that the high-risk patients were more likely to benefit from ICI treatments, including PD-1/PD-L1/PD-L2 blocker, CTLA-4 blocker and combination therapy, compared with low-risk patients (Figure 5E). The gene discussed is CTLA4; the disease is neoplasm.